The application of immune checkpoint modulators, such as anti-CTLA-4 and anti-PD-1 antibodies, along with adoptive immune cell therapies like CAR-T cells, has demonstrated unexpected anti-tumor effects across a spectrum of cancers, ushering in a new era for cancer treatment (28). This evidence concerns the gene CTLA4 and cancer.